Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19862 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Hemmat Abd El-Salam Ahmed Salama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Family Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Ivermectin, Colchicine, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19). Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded. Sealed envelopes were used for randomization of intervention or control. Patients are followed until there was improvement of symptoms and no development of new symptoms for over one month.
Results
A total of 120 patients (40.16 ± 10.74 years) with COVID-19 were enrolled; 40 patients in each arm. Out of them, 44 (36.6%) were male and 76 (63.4%) were female. Fever and cough were the predominant symptoms in each group. There was no statistically significant difference in the mean duration of fever between the ivermectin, colchicine, and control groups (7.3 ± 1.68, 6.6 ± 1.58, and 7.075 ± 1.58 days, respectively). The majority of patients (67.5%, 70%, and 72.5%) were completely cured within 10 days of infection, with no differences between the three groups (p > 0.05). A statistically significant improvement of inflammatory markers occurred in each of the three groups over time with no statistically significant difference between them.
Conclusions
Ivermectin and colchicine have no beneficial effect over standard care in the treatment of COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Family Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Clinical Pharmacology Department, Faculty of Medicine, Galala University, Suez, Egypt.
Zitieren
APA
Ahmed Salama, H. A. E., Ahmed, E. E., Amin, G. E. E., Allam, M. F., Hassan, A. N. E., & Hassan El Shayeb, M. A. E. R. (2024). Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19862
Vancouver
Ahmed Salama HAE, Ahmed EE, Amin GEE, Allam MF, Hassan ANE, Hassan El Shayeb MAER. Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19862
BibTeX
@article{AhmedSalama2024,
author = {Ahmed Salama, Hemmat Abd El-Salam and Ahmed, Eman El-Sayed and Amin, Ghada Essam El-Din and Allam, Mohamed Farouk and Hassan, Ahmed Nour El-Din and Hassan El Shayeb, Mohamed Abd El Rahman},
title = {Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19862}
}
EUVIMED